Ab&B Bio Tech Co Ltd JS

Ab&B Bio Tech Co Ltd JS Liabilities

The The Liabilities of Ab&B Bio Tech Co Ltd JS (2627.HK) as of Oct 22, 2026 is 1.47 B CNY. In the previous year, The Liabilities was 756.47 M CNY — a change of 93.83% (higher).

Liabilities

1.47 BCNY

YoY

93.83%

Last updated:

In 2024, Ab&B Bio Tech Co Ltd JS's total liabilities amounted to 1.47 B CNY, a 93.83% difference from the 756.47 M CNY total liabilities in the previous year.

The Ab&B Bio Tech Co Ltd JS Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2023
756.47 M CNY
Jan 1, 2024
1.47 B CNY
The Ab&B Bio Tech Co Ltd JS Liabilities history
YEARLiabilitiesYoY
1.47 BCNY+93.83%
756.47 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ab&B Bio Tech Co Ltd JS Stock analysis

What does Ab&B Bio Tech Co Ltd JS do? Ab&B Bio Tech Co Ltd JS generates revenue through the research, development, manufacturing, and commercialization of vaccines. The company's core products include the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, alongside 11 other vaccine candidates. It primarily serves the domestic market in China, focusing on vaccine solutions for public health needs. The company's business model centers on bringing its vaccine pipeline to market through domestic sales and commercialization efforts. The firm operates within the biotechnology industry, specifically targeting vaccine development and production. Its product portfolio consists of two core vaccines and 11 additional candidates, all aimed at addressing infectious disease prevention. Ab&B Bio Tech Co Ltd JS leverages its domestic market presence to sell these products, with no mention of international sales or partnerships in the business description. The company's revenue streams derive from the commercialization of its vaccine pipeline, including the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate. It focuses on the Chinese domestic market for product distribution and sales, with no indication of export activities or foreign market engagement. Ab&B Bio Tech Co Ltd JS's business model emphasizes in-country development and sales of vaccines to meet local healthcare demands. Ab&B Bio Tech Co Ltd JS is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Ab&B Bio Tech Co Ltd JS's Liabilities

Ab&B Bio Tech Co Ltd JS's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ab&B Bio Tech Co Ltd JS's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ab&B Bio Tech Co Ltd JS's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ab&B Bio Tech Co Ltd JS's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ab&B Bio Tech Co Ltd JS’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ab&B Bio Tech Co Ltd JS stock

The Liabilities of Ab&B Bio Tech Co Ltd JS is 1.47 B CNY in 2024.

The Liabilities of Ab&B Bio Tech Co Ltd JS changed from 756.47 M CNY to 1.47 B CNY, representing a 93.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Ab&B Bio Tech Co Ltd JS since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Ab&B Bio Tech Co Ltd JS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Ab&B Bio Tech Co Ltd JS

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Ab&B Bio Tech Co Ltd JS